MRI-identified multidimensional nodal features predict survival and concurrent chemotherapy benefit for stage II nasopharyngeal carcinoma
By:
References
- Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet 2019; 394: 64-80. doi: 10.1016/s0140-6736(19)30956-0
- Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, et al. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol 2014; 110: 398-403. doi: 10.1016/j.radonc.2013.10.020
- Tian YM, Liu MZ, Zeng L, Bai L, Lin CG, Huang SM, et al. Long-term outcome and pattern of failure for patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. Head Neck 2019; 41: 1246-52. doi: 10.1002/hed.25545
- National Comprehensive Cancer Network. NCCN Guidelines in Oncology. Head and Neck Cancers. Version 2.2022. [Internet]. [cited 2022 Apr 26]. Available at https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1437
- Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 2011; 103: 1761-70. doi: 10.1093/jnci/djr432
- Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX, et al. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys 2012; 82: 327-33. doi: 10.1016/j.ijrobp.2010.09.011
- Huang X, Chen X, Zhao C, Wang J, Wang K, Wang L, et al. Adding concurrent chemotherapy to intensity-modulated radiotherapy does not improve treatment outcomes for stage II nasopharyngeal carcinoma: a phase 2 multicenter clinical trial. Front Oncol 2020; 10: 1314. doi: 10.3389/fonc.2020.01314
- Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, et al. Nasopharyngeal carcinoma: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol 2021; 32: 452-65. doi: 10.1016/j. annonc.2020.12.007
- Sun XS, Li XY, Xiao BB, Liu SL, Chen QY, Tang LQ, et al. Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: a study based on a phase III randomized clinical trial with 10-year follow-up. Oral Oncol 2020; 100: 104490. doi: 10.1016/j.oraloncology.2019.104490
- He SS, Wang CT, Peng ZW, Ren YF, Lu LX, Chen RW, et al. Development and external validation of a nomogram for predicting the overall survival of patients with stage II nasopharyngeal carcinoma after curative treatment. Cancer Manag Res 2019; 11: 4403-12. doi: 10.2147/CMAR.S202151
- Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, et al. Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol 2021; 39: 840-59. doi: 10.1200/jco.20.03237
- Du YY, Luo DH, Sun XS, Tang LQ, Mai HQ, Chen QY, et al. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: a cohort study. Cancer Med 2019; 8: 6841-52. doi: 10.1002/cam4.2481
- Hu Y, Lu T, Huang SH, Lin S, Chen Y, Fang Y, et al. High-grade radiologic extra-nodal extension predicts distant metastasis in stage II nasopharyngeal carcinoma. Head Neck 2019; 41: 3317-27. doi: 10.1002/hed.25842
- Liu Y, Chen S, Dong A, Ai F, Quan T, Cui C, et al. Nodal grouping in naso-pharyngeal carcinoma: prognostic significance, N classification, and a marker for the identification of candidates for induction chemotherapy. Eur Radiol 2020; 30: 2115-24. doi: 10.1007/s00330-019-06537-6
- Lin TY, Lan MY, Tsou HH, Ho CY, Twu CW, Liu YC, et al. Survival impacts of different nodal characteristics and T-classification in N3 nasopharyngeal carcinoma patients. Oral Oncol 2020; 108: 104820. doi: 10.1016/j.oraloncology.2020.104820
- Chen X, Cao X, Jing B, Xia W, Ke L, Xiang Y, et al. Prognostic and treatment guiding significance of MRI-based tumor burden features and nodal necrosis in nasopharyngeal carcinoma. Front Oncol 2020; 10: 537318. doi: 10.3389/fonc.2020.537318
- Ai QY, King AD, Poon DMC, Mo FKF, Hui EP, Tong M, et al. Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx. Oral Oncol 2019; 88: 124-30. doi: 10.1016/j. oraloncology.2018.11.007
- Lu T, Hu Y, Xiao Y, Guo Q, Huang SH, O’Sullivan B, et al. Prognostic value of radiologic extranodal extension and its potential role in future N classification for nasopharyngeal carcinoma. Oral Oncol 2019; 99: 104438. doi: 10.1016/j. oraloncology.2019.09.030
- Lan M, Huang Y, Chen CY, Han F, Wu SX, Tian L, et al. Prognostic value of cervical nodal necrosis in nasopharyngeal carcinoma: analysis of 1800 patients with positive cervical nodal metastasis at MR imaging. Radiology 2015; 276: 619. doi: 10.1148/radiol.15141251
- Li JY, Huang CL, Luo WJ, Zhang Y, Tang LL, Peng H, et al. An integrated model of the gross tumor volume of cervical lymph nodes and pretreatment plasma Epstein-Barr virus DNA predicts survival of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Ther Adv Med Oncol 2019; 11: 1758835919877729. doi: 10.1177/1758835919877729
- Huang CL, Chen Y, Guo R, Mao YP, Xu C, Tian L, et al. Prognostic value of MRI-determined cervical lymph node size in nasopharyngeal carcinoma. Cancer Med 2020; 9: 7100-6. doi: 10.1002/cam4.3392
- Ma H, Liang S, Cui C, Zhang Y, Xie F, Zhou J, et al. Prognostic significance of quantitative metastatic lymph node burden on magnetic resonance imaging in nasopharyngeal carcinoma: a retrospective study of 1224 patients from two centers. Radiother Oncol 2020; 51: 40-6. doi: 10.1016/j. radonc.2020.07.023
- Zhou X, Ou X, Yang Y, Xu T, Shen C, Ding J, et al. Quantitative metastatic lymph node regions on magnetic resonance imaging are superior to AJCC N classification for the prognosis of nasopharyngeal carcinoma. J Oncol 2018; 2018: 9172585. doi: 10.1155/2018/9172585
- van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology 1990; 177: 379-84. doi: 10.1148/radiology.177.2.2217772
- Meira-Machado L, Cadarso-Suarez C, Gude F, Araujo A. smoothHR: an R package for pointwise nonparametric estimation of hazard ratio curves of continuous predictors. Comput Math Methods Med 2013; 2013: 745742. doi: 10.1155/2013/745742
- Liu DH, Zhou XY, Pan YG, Chen S, Ye ZH, Chen GD. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: a propensity score matching study. Cancer Med 2020; 9: 1287-97. doi: 10.1002/cam4.2785
- Luo S, Zhao L, Wang J, Xu M, Li J, Zhou B, et al. Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China. Head Neck 2014; 36: 841-7. doi: 10.1002/hed.23386
- Kang MK, Oh D, Cho KH, Moon SH, Wu HG, Heo D, et al. Role of chemotherapy in stage II nasopharyngeal carcinoma treated with curative radiotherapy. Cancer Res Treat 2015; 47: 871-8. doi: 10.4143/crt.2014.141
- Lee VH, Kwong DL, Leung TW, Choi CW, O’Sullivan B, Lam KO, et al. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int J Cancer 2019; 144: 1713-22. doi: 10.1002/ijc.31856
- Guo R, Tang LL, Mao YP, Du XJ, Chen L, Zhang ZC, et al. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma. Cancer 2019; 125: 79-89. doi: 10.1002/cncr.31741
- Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24: 5414-18. doi: 10.1200/JCO.2006.07.7982
- Sun XS, Chen WH, Liu SL, Liang YJ, Chen QY, Guo SS, et al. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: a propensity score matching analysis using a large cohort. Cancer Med 2019; 8: 4214-25. doi: 10.1002/cam4.2343
Language: English
Page range: 479 - 487
Submitted on: Sep 10, 2022
Accepted on: Oct 11, 2022
Published on: Dec 13, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2022 Yang Liu, Jianghu Zhang, Jingbo Wang, Runye Wu, Xiaodong Huang, Kai Wang, Yuan Qu, Xuesong Chen, Yexiong Li, Ye Zhang, Junlin Yi, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.